A highly-sensitive cell free DNA assay in gastrointestinal tumors - A prospective observational study

A highly-sensitive cell free DNA assay in gastrointestinal tumors - A prospective observational study - An observational study of highly-sensitive cell free DNA assay

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050428

Enrollment

500

Registered

2023-03-01

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal malignant tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Written consent has been obtained from the patient after a full explanation of the study content has been given prior to enrollment in the study. 2) Patients must be at least 18 years of age at the time of enrollment. 3) Patients must have a primary malignant tumor of the gastrointestinal tract. 4) Patients are scheduled to receive either systemic drug therapy, radiation therapy, or surgery. (Patients on systemic drug therapy can be enrolled after progression of prior therapy and before initiation of the next therapy.)

Exclusion criteria

Exclusion criteria: 1) The patient has active overlapping cancers (concurrent overlapping/multiple cancers). 2) Other conditions deemed inappropriate by the physician.

Design outcomes

Primary

Measure	Time frame
cfDNA dynamics (Percentage of cfDNA detected at each test time point and its trend)	—

Countries

Japan

Contacts

Public ContactHiroya Taniguchi

Aichi Cancer Center Hospital Department of Clinical Oncology

h.taniguchi@aichi-cc.jp052-762-6111

Outcome results